Results 211 to 220 of about 44,894 (310)

A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available ...
Ian E. Templeton, Chara Litou, Hannah M. Jones, Julie Mackey Ahsan, Marilyn Tabachri, Mollie Leoni, Amitava Mitra   +6 more
wiley   +1 more source

Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models to Investigate the Effect of CYP2D6 Polymorphism on Metoclopramide Systemic Exposure. [PDF]

Pharmaceuticals (Basel)
Shahzad I, Zamir A, Rasool MF, Alali AS, Hussain I, Alqahtani F.   +5 more
europepmc   +1 more source

Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs

United European Gastroenterology Journal, Volume 14, Issue 7, September 2026.
ABSTRACT Background Functional dyspepsia (FD) is a prevalent disorder of gut‐brain interaction (DGBI) and is associated with substantial impact on health care utilisation. However, analyses examining patient‐specific characteristics that contribute to this burden remain limited.
Daan H. C. A. Bosch, Brigitte A. B. Essers, Abraham B. Beckers, Johanna T. W. Snijkers, Bjorn Winkens, Ad A. M. Masclee, Daniel Keszthelyi   +6 more
wiley   +1 more source

A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression. [PDF]

Drug Des Devel Ther
Cheung N.
europepmc   +1 more source

Low‐Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle‐Aged and Older Adults: Study Protocol for a Triple‐Blind, Randomised, Placebo‐Controlled Trial

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 3, September 2026.
ABSTRACT Systemic chronic inflammation contributes to the development of many age‐related chronic diseases and represents a promising target for interventions aiming at promoting healthy aging. Fisetin is a naturally occurring flavonoid with anti‐inflammatory, antioxidant and senolytic effects in vitro and in animal models, but evidence from randomised
Juliette Tavenier, Magnus Berglind, Line Fleischer Hach, Louise Westberg Strejby Christensen, Maria Jana Masarikova, Rafal Yahya, Mette Bendtz Lindstrøm, Baker Nawfal Jawad, Anna Zatkova, Rikke Lundsgaard Nielsen, Helle Gybel Juul‐Larsen, Thomas Kallemose, Jan Olof Nehlin, Morten Baltzer Houlind, Ove Andersen, Line Jee Hartmann Rasmussen   +15 more
wiley   +1 more source

Role of cytochrome phenotyping in patients with chronic noncancer pain with inadequate response to tramadol. [PDF]

Pain Rep
Montmeat D, Declèves X, Puszkiel A, Perrot S, Trouvin AP.   +4 more
europepmc   +1 more source

Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐Yl) Derivatives as EGFR Inhibitors Targeting EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S in NSCLC

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
Rational Design, Synthesis, Biological Evaluation, and In Silico Investigation of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting Wild‐Type and Mutant EGFR in NSCLC. ABSTRACT Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor ...
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Manjushree BV, Anguraj Moulishankar, Viney Chawla, Pooja A. Chawla   +6 more
wiley   +1 more source

A de novo algorithm for allele reconstruction from Oxford nanopore amplicon reads, with application to CYP2D6. [PDF]

Bioinformatics
Brown SD, Dreolini L, Minor A, Mozel M, Wong N, Mar S, Lieu A, Khan M, Carlson A, Hrynchak M, Holt RA, Missirlis PI.   +11 more
europepmc   +1 more source

Evaluation of the Effect of Cendakimab on the Pharmacokinetics of CYP Probe Drugs in Patients With Eosinophilic Esophagitis

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Cendakimab is a humanized monoclonal antibody that inhibits interleukin‐13 binding to its receptors. Although not expected to share clearance pathways with small molecules, its use in eosinophilic esophagitis, a type 2 inflammatory disease, may indirectly affect cytochrome P450 activity by modulating cytokine signaling affecting certain ...
Peijin Zhang, Christina M. Charriez, Bindu Murthy, Shenita Basdeo, Yanying Wang, Leonel Villa‐Caballero, Hamza Kandoussi, Claudia H. M. C. De Oliveira, David A. Leiman, Jie Li, Urvi Aras   +10 more
wiley   +1 more source

CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank. [PDF]

Pharmaceuticals (Basel)
Cohen T, Rebibo Demry E, Young AH, Kleine Schaars K, Juruena M, Schulze TG, Kaprio J, Psy-PGx Consortium, van Westrhenen R, Shomron N.   +9 more
europepmc   +1 more source